혈소판 감소증 : 세계 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(주요 32개 시장)(2025-2035년)

Global Thrombocytopenia Market Outlook

Thelansis's "Global Thrombocytopenia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Thrombocytopenia treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Thrombocytopenia Overview

Thrombocytopenia is a condition characterized by an abnormally low platelet count that can result from reduced platelet production in the bone marrow, increased destruction or consumption of platelets, or sequestration in an enlarged spleen. Clinical severity ranges from asymptomatic laboratory findings to life-threatening bleeding, depending on the underlying cause and platelet count. Management has traditionally focused on treating the underlying disorder, providing supportive care such as platelet transfusions when needed, and using immunosuppressive therapies for immune-mediated forms. Recent advances have introduced mechanism-specific treatments, including agents that stimulate platelet production and therapies that target the immune pathways responsible for platelet destruction in selected patients. New immune-targeted drug classes continue to expand treatment options for immune-mediated thrombocytopenia, while ongoing research aims to develop more precise, cause-specific therapies. For stakeholders, thrombocytopenia reflects a field gradually shifting from supportive management toward mechanism-driven treatment tailored to the underlying disease.

Key Highlights

• In Germany, the prevalent Thrombocytopenia population is projected to increase from 145,075 in 2025 to 148,284 by 2035.
• Thrombocytopenia is characterized by low platelet counts, increasing the risk of bleeding and associated complications.
• Disease burden remains significant, particularly in patients with chronic or treatment-induced thrombocytopenia.
• Significant unmet need remains for therapies that provide sustained platelet recovery with improved safety.

Market Overview

• The France Thrombocytopenia market is projected to grow from $95M in 2025 to $160M by 2035.
• Market growth is driven by:
• Increasing adoption of thrombopoietin receptor agonists and targeted therapies
• Improved diagnosis and management of chronic thrombocytopenia
• Future growth will depend on therapies that offer durable platelet response and reduced bleeding risk.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Qilu Pharmaceutical Co., Ltd.
• Gliknik Inc.
• Sobi, Inc.
• Sanofi
• Incyte Corporation
• Jian Zhu
• Nuvig Therapeutics, Inc.
• Eli Lilly and Company
• Dizal Pharmaceuticals
• Shanghai Escugen Biotechnology Co., Ltd.
• Argenx
• CASI Pharmaceuticals, Inc.
• Amgen
• Novartis Pharmaceuticals
• Jiangsu HengRui Medicine Co., Ltd.
• Sichuan Clover Biopharmaceuticals, Inc.
• Hutchmed
• Kedrion S.p.A.
• Takeda
• Keymed Biosciences Co., Ltd.
• Oscotec Inc.
• Alpine Immune Sciences, Inc.
• Ouro Medicines
• Chugai Pharmaceutical
• Celgene

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)